• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

下调 Mcl-1 可增强顺铂联合新型纤维嵌合溶瘤腺病毒治疗的促凋亡反应。

Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.

机构信息

Institute of Hematology, the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou 310003, PR China.

出版信息

Oncol Rep. 2012 Apr;27(4):971-8. doi: 10.3892/or.2012.1636. Epub 2012 Jan 16.

DOI:10.3892/or.2012.1636
PMID:22266706
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3583558/
Abstract

The aim of this study was to examine the effects of SG511, a novel fiber chimeric oncolytic adenovirus with E1B 55-kDa deleted, combined with cisplatin on cancer cells and to identify their underlying mechanisms. The combined effect of SG511 and cisplatin on HeLa and HT-29 cells was assessed by a crystal violet assay and an MTT assay, followed by combination index analysis. Cell apoptosis was evaluated by DAPI staining and visualized by fluorescein-mediated signal detection. Mitochondrial membrane potential was detected by flow cytometric analysis of Rhodamine 123 accumulation. The activation of the caspase pathway and the expression of Bcl-2 family proteins were examined by western blotting. Results show that SG511 vector infected various human cancer cell lines and induced growth inhibition effectively. Of note, SG511 synergistically enhanced the anti-proliferative activity of cisplatin, a DNA-damaging agent, against HeLa and HT-29 cells in vitro, concomitantly with increased apoptosis and activation of the mitochondrial pathway. Furthermore, treatment with SG511 alone or in combination with cisplatin resulted in reduced expression the anti-apoptotic Bcl-2 family member Mcl-1 in HeLa and HT-29 cells. Importantly, this combination did not increase the growth inhibitory effects of cisplatin on human normal liver cells. Collectively, SG511, a novel fiber chimeric oncolytic adenovirus, sensitizes cancer cells to apoptosis by reducing anti-apoptotic Mcl-1 protein levels.

摘要

本研究旨在探讨新型纤维嵌合溶瘤腺病毒 SG511(缺失 E1B55kDa)联合顺铂对癌细胞的作用,并鉴定其潜在机制。通过结晶紫法和 MTT 法评估 SG511 与顺铂联合对 HeLa 和 HT-29 细胞的联合效应,随后进行合并指数分析。通过 DAPI 染色和荧光素介导的信号检测评估细胞凋亡。通过 Rhodamine 123 积累的流式细胞术分析检测线粒体膜电位。通过 Western blot 检测 caspase 途径的激活和 Bcl-2 家族蛋白的表达。结果表明,SG511 载体感染各种人癌细胞系并有效诱导生长抑制。值得注意的是,SG511 与顺铂(一种 DNA 损伤剂)联合,协同增强了对 HeLa 和 HT-29 细胞的体外增殖抑制活性,同时增加了细胞凋亡和线粒体途径的激活。此外,SG511 单独或联合顺铂处理导致 HeLa 和 HT-29 细胞中抗凋亡 Bcl-2 家族成员 Mcl-1 的表达减少。重要的是,这种组合并未增加顺铂对人正常肝细胞的生长抑制作用。总之,新型纤维嵌合溶瘤腺病毒 SG511 通过降低抗凋亡 Mcl-1 蛋白水平使癌细胞对凋亡敏感。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/d732496b9a99/OR-27-04-0971-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/173d1d1c5477/OR-27-04-0971-g0.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/ae9a972eca0f/OR-27-04-0971-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/8786444e978c/OR-27-04-0971-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/0d78ef6d4921/OR-27-04-0971-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/d732496b9a99/OR-27-04-0971-g4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/173d1d1c5477/OR-27-04-0971-g0.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/ae9a972eca0f/OR-27-04-0971-g1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/8786444e978c/OR-27-04-0971-g2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/0d78ef6d4921/OR-27-04-0971-g3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/dd36/3583558/d732496b9a99/OR-27-04-0971-g4.jpg

相似文献

1
Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.下调 Mcl-1 可增强顺铂联合新型纤维嵌合溶瘤腺病毒治疗的促凋亡反应。
Oncol Rep. 2012 Apr;27(4):971-8. doi: 10.3892/or.2012.1636. Epub 2012 Jan 16.
2
Markedly enhanced cytolysis by E1B-19kD-deleted oncolytic adenovirus in combination with cisplatin.E1B-19kD缺失的溶瘤腺病毒与顺铂联合使用时细胞溶解作用显著增强。
Hum Gene Ther. 2006 Apr;17(4):379-90. doi: 10.1089/hum.2006.17.379.
3
Combination of bladder cancer-specific oncolytic adenovirus gene therapy with cisplatin on bladder cancer in vitro.膀胱癌特异性溶瘤腺病毒基因治疗与顺铂联合用于体外膀胱癌治疗
Tumour Biol. 2014 Nov;35(11):10879-90. doi: 10.1007/s13277-014-2353-7. Epub 2014 Aug 2.
4
Homoharringtonine acts synergistically with SG235-TRAIL, a conditionally replicating adenovirus, in human leukemia cell lines.高三尖杉酯碱与条件复制型腺病毒 SG235-TRAIL 联合作用于人白血病细胞系。
Acta Pharmacol Sin. 2009 Nov;30(11):1529-36. doi: 10.1038/aps.2009.147. Epub 2009 Oct 12.
5
Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin.携带XAF1的溶瘤腺病毒与顺铂联合对肝癌肿瘤生长的协同抑制作用
J Cancer Res Clin Oncol. 2015 Mar;141(3):419-29. doi: 10.1007/s00432-014-1835-8. Epub 2014 Sep 21.
6
A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.通过 E1A 依赖性 p21 和 MDM2 抑制实现基因工程腺病毒介导的肿瘤特异性 p53 过表达的新型凋亡机制。
Eur J Cancer. 2012 Sep;48(14):2282-91. doi: 10.1016/j.ejca.2011.12.020. Epub 2012 Jan 13.
7
The antitumor efficacy of IL-24 mediated by E1A and E1B triple regulated oncolytic adenovirus.E1A 和 E1B 三重调控的溶瘤腺病毒介导的 IL-24 抗肿瘤疗效。
Cancer Biol Ther. 2010 Aug 1;10(3):242-50. doi: 10.4161/cbt.10.3.12308. Epub 2010 Aug 10.
8
Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia.通过诱导白血病细胞自噬性死亡,表达Beclin-1的溶瘤腺病毒具有强大的抗肿瘤活性。
Oncotarget. 2013 Jun;4(6):860-74. doi: 10.18632/oncotarget.1018.
9
Dichloroacetate (DCA) enhances tumor cell death in combination with oncolytic adenovirus armed with MDA-7/IL-24.二氯乙酸(DCA)与携带 MDA-7/IL-24 的溶瘤腺病毒联合使用可增强肿瘤细胞死亡。
Mol Cell Biochem. 2010 Jul;340(1-2):31-40. doi: 10.1007/s11010-010-0397-6. Epub 2010 Feb 18.
10
E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.E1B 55千道尔顿缺失的Ad5/F35纤维嵌合腺病毒,一种用于B淋巴细胞恶性肿瘤的潜在溶瘤剂。
J Gene Med. 2009 Jun;11(6):477-85. doi: 10.1002/jgm.1326.

引用本文的文献

1
Low extracellular pH enhances TRAIL-induced apoptosis by downregulating Mcl-1 expression.低细胞外pH值通过下调Mcl-1表达增强TRAIL诱导的细胞凋亡。
Exp Cell Res. 2025 Apr 1;447(1):114481. doi: 10.1016/j.yexcr.2025.114481. Epub 2025 Feb 28.
2
Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits.溶瘤病毒与小分子疗法的联合应用:互利共赢。
Cancers (Basel). 2021 Jul 6;13(14):3386. doi: 10.3390/cancers13143386.
3
Oncolytic virotherapy promotes radiosensitivity in soft tissue sarcoma by suppressing anti-apoptotic MCL1 expression.

本文引用的文献

1
Correlation between Mcl-1 and pAKT protein expression in colorectal cancer.结直肠癌中Mcl-1与pAKT蛋白表达的相关性
Int J Clin Exp Pathol. 2010 Oct 12;3(8):768-74.
2
Mcl-1 is critical for survival in a subgroup of non-small-cell lung cancer cell lines.Mcl-1 对于非小细胞肺癌细胞系亚群的存活至关重要。
Oncogene. 2011 Apr 21;30(16):1963-8. doi: 10.1038/onc.2010.559. Epub 2010 Dec 6.
3
Unity and diversity in the human adenoviruses: exploiting alternative entry pathways for gene therapy.人类腺病毒的统一性和多样性:利用替代进入途径进行基因治疗。
溶瘤病毒治疗通过抑制抗凋亡 MCL1 表达促进软组织肉瘤的放射敏感性。
PLoS One. 2021 Apr 22;16(4):e0250643. doi: 10.1371/journal.pone.0250643. eCollection 2021.
4
Inhibition of Kpnβ1 mediated nuclear import enhances cisplatin chemosensitivity in cervical cancer.抑制 Kpnβ1 介导的核输入可增强宫颈癌对顺铂的化疗敏感性。
BMC Cancer. 2021 Feb 2;21(1):106. doi: 10.1186/s12885-021-07819-3.
5
Role of zoledronic acid in oncolytic virotherapy: Promotion of antitumor effect and prevention of bone destruction.唑来膦酸在溶瘤病毒疗法中的作用:增强抗肿瘤效果并预防骨质破坏。
Cancer Sci. 2017 Sep;108(9):1870-1880. doi: 10.1111/cas.13316. Epub 2017 Aug 3.
6
Cancer immunotherapy via combining oncolytic virotherapy with chemotherapy: recent advances.溶瘤病毒疗法与化疗联合的癌症免疫疗法:最新进展
Oncolytic Virother. 2016 Jan 6;5:1-13. doi: 10.2147/OV.S66083. eCollection 2016.
7
Ablation of MCL1 expression by virally induced microRNA-29 reverses chemoresistance in human osteosarcomas.病毒诱导的 microRNA-29 对 MCL1 表达的消融可逆转人骨肉瘤的化疗耐药性。
Sci Rep. 2016 Jun 30;6:28953. doi: 10.1038/srep28953.
Biochem J. 2010 Nov 1;431(3):321-36. doi: 10.1042/BJ20100766.
4
Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosis.获得性激活 Akt/环氧化酶-2/Mcl-1 通路使肺癌细胞对细胞凋亡产生抗性。
Mol Pharmacol. 2010 Mar;77(3):416-23. doi: 10.1124/mol.109.061226. Epub 2009 Nov 23.
5
Intraperitoneal administration of telomerase-specific oncolytic adenovirus sensitizes ovarian cancer cells to cisplatin and affects survival in a xenograft model with peritoneal dissemination.腹腔内给予端粒酶特异性溶瘤腺病毒可使卵巢癌细胞对顺铂敏感,并影响腹腔播散异种移植模型中的生存。
Cancer Gene Ther. 2010 Jan;17(1):11-9. doi: 10.1038/cgt.2009.44.
6
Effective gene-viral therapy of leukemia by a new fiber chimeric oncolytic adenovirus expressing TRAIL: in vitro and in vivo evaluation.新型纤维嵌合溶瘤腺病毒表达 TRAIL 对白血病的有效基因-病毒治疗:体外和体内评价。
Mol Cancer Ther. 2009 May;8(5):1387-97. doi: 10.1158/1535-7163.MCT-08-0962. Epub 2009 May 5.
7
Preclinical evaluation of synergistic effect of telomerase-specific oncolytic virotherapy and gemcitabine for human lung cancer.端粒酶特异性溶瘤病毒疗法与吉西他滨联合治疗人类肺癌的协同效应的临床前评估
Mol Cancer Ther. 2009 Apr;8(4):980-7. doi: 10.1158/1535-7163.MCT-08-0901.
8
Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide.雷帕霉素或环磷酰胺联合治疗可增强全身给药的溶瘤痘苗病毒疗法对恶性胶质瘤的疗效。
Clin Cancer Res. 2009 Apr 15;15(8):2777-88. doi: 10.1158/1078-0432.CCR-08-2342. Epub 2009 Apr 7.
9
E1B 55-kDa deleted, Ad5/F35 fiber chimeric adenovirus, a potential oncolytic agent for B-lymphocytic malignancies.E1B 55千道尔顿缺失的Ad5/F35纤维嵌合腺病毒,一种用于B淋巴细胞恶性肿瘤的潜在溶瘤剂。
J Gene Med. 2009 Jun;11(6):477-85. doi: 10.1002/jgm.1326.
10
Enhancement of tumor cell death by combining cisplatin with an oncolytic adenovirus carrying MDA-7/IL-24.顺铂与携带MDA-7/IL-24的溶瘤腺病毒联合使用增强肿瘤细胞死亡
Acta Pharmacol Sin. 2009 Apr;30(4):467-77. doi: 10.1038/aps.2009.16. Epub 2009 Mar 9.